Orographic Financial Advisors LLC Takes Position in Amgen Inc. $AMGN

Orographic Financial Advisors LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 1,442 shares of the medical research company’s stock, valued at approximately $507,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dogwood Wealth Management LLC boosted its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC increased its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Tower View Wealth Management LLC raised its position in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the period. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in Amgen in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AMGN shares. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Barclays upped their price target on Amgen from $350.00 to $360.00 and gave the company an “equal weight” rating in a research note on Wednesday. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research note on Friday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $357.00.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion supporting broader use of Amgen’s cholesterol drug Repatha in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing a significant reduction in major cardiovascular events, could expand Repatha’s addressable market in Europe pending final regulatory approval. Amgen Wins Backing In Europe For Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The announcement reinforces the company’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen’s experimental monthly weight-loss medicine has six Phase 3 trials underway. Success could give the company a significant entry point into the rapidly growing obesity-drug market and provide a long-term growth catalyst, although the program remains unproven. Amgen Weight-Loss Drug Pipeline
• Neutral Sentiment: Analysts are moderately optimistic after Amgen’s strong longer-term performance, but valuation assessments are mixed: discounted-cash-flow analysis indicates upside, while market multiples appear closer to fair value. Investors are also awaiting further detail on second-quarter operating metrics.
• Negative Sentiment: Barclays maintained an Equal Weight/Hold rating and raised its price target only to $360, below Amgen’s recent trading level. The target implies limited near-term upside and reflects caution after the stock’s sizable advance. Barclays Keeps Hold Rating on Amgen
• Negative Sentiment: Amgen’s obesity-drug ambitions face formidable competition from established Eli Lilly and Novo Nordisk products. Investors may remain cautious until clinical data demonstrate that Amgen’s candidate can compete on efficacy, safety, dosing convenience, and commercialization.

Amgen Stock Performance

Shares of AMGN opened at $387.64 on Friday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $398.00. The stock has a market capitalization of $209.21 billion, a PE ratio of 26.98, a PEG ratio of 3.92 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a 50-day simple moving average of $355.69 and a 200-day simple moving average of $353.55.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.90 earnings per share. On average, analysts predict that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. Amgen’s dividend payout ratio is currently 70.15%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.